Loading…
To require the Secretary of Health and Human Services to conduct a study on pharmacy benefit manager audit practices.
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
80pct
53d open
vs 10,564 other HR bills in the 118th — cohort avg 68d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2024 · fourth_quarter · Health Issues
H.R.10050: Pharmacist Audit & Compensation Transparency Act, a bill to require the Secretary of Health and Human Services to conduct a study on pharmacy benefit manager audit practices. S.2305: The Biosimilar Red Tape Elimination Act-legislation addressing the standards for interoperability for biosimilars and requirements for switching studies. Division E Healthcare of H.R.10445, Further Continuing Appropriation and Disaster Relief Supplemental Appropriations Act of 2025: provisions regulation PBMs.
Client expense: $100,000 · Firm income: Not reported
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Health Issues
H. R. 10050, Pharmacist Audit & Compensation Transparency Act; S. 2305, The Biosimilar Red Tape Elimination Act; H.R. 10445, Further Continuing Appropriation and Disaster Relief Supplemental Appropriations Act of 2025
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE